Modifications of whole blood filterability during acute myocardial infarction.
Experimental evidences underline that hemorheological alterations observed in acute myocardial infarction (AMI) are strictly involved in the decreased perfusion of the damaged area and in the extension of the necrotic regions. We have analyzed whole blood filterability as an index of erythrocyte deformability in 60 AMI patients compared with 30 patients with non-acute coronary artery disease and 52 healthy subjects. Nucleopore polycarbonate membranes with a pore diameter of 5 microm and a filtering pressure of -20 cm H2O were used. The results are expressed as the volume of whole blood filtered in 1 minute (index of filterability, IF). In normal subjects IF was 1.16 +/- 0.24. Among AMI patients IF was 0.70 +/- 0.30 at admission, 0.68 +/- 017 at day 10 and 0.78 +/- 0.14 at day 20. These values were significantly lower than those obtained in normal subjects and in patients with non-acute coronary artery disease. In addition, AMI patients treated with thrombolytic therapy showed, at admission, a significantly higher IF value than that obtained in patients who did not receive thrombolytic treatment (0.85 +/- 0.34 vs 0.60 +/- 0.22; p < 0.01). These results demonstrate an evident reduction of whole blood filterability in AMI patients that may be considered as an index of erythrocyte deformability. Thrombolytic therapy seems to have a positive effect on blood filterability and may produce beneficial effects through its therapeutical action other than the lysis of the coronary thrombus.
Penco
M
M
Department of Internal Medicine, University of L'Aquila, Italy.
Romano
S
S
Dagianti
A
A
Tozzi-Ciancarelli
M G
MG
Dagianti
A
A
D000208:Acute Disease; D000368:Aged; D001809:Blood Viscosity / Q000187:drug effects*; D048909:Diabetes Complications; D004907:Erythrocyte Deformability / Q000187:drug effects*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005374:Filtration / Q000295:instrumentation; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D017202:Myocardial Ischemia / Q000097:blood / Q000150:complications; D009206:Myocardium / Q000473:pathology; D009336:Necrosis; D011076:Polycarboxylate Cement; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents; D008567:Membranes, Artificial; D011076:Polycarboxylate Cement; C005506:polycarbonate; D005340:Fibrinogen